Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic peptide derived from the internal region of human ELAC2|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.4, with 150mM NaCl, 50% glycerol|
|Contains||0.02% sodium azide|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:100|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
The protein encoded by this gene has a C-terminal domain with tRNA 3 processing endoribonuclease activity, which catalyzes the removal of the 3' trailer from precursor tRNAs. The protein also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in this gene result in an increased risk of prostate cancer. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009].
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
elaC homolog 2; ElaC homolog protein 2; elaC-like protein 2; ELC2; Heredity prostate cancer protein 2; HPC2; putative prostate cancer susceptibility protein HPC2/ELAC2; Ribonuclease Z 2; RNase Z 2; tRNA 3 endonuclease 2; tRNase Z (long form); tRNase Z 2; Zinc phosphodiesterase ELAC protein 2
COXPD17; ELAC2; ELC2; HPC2